Dominican Republic vs Georgia: Average cost of multi drug-resistant tuberculosis treatment
Dominican Republic
1,650 constant 2022 US$
in 2024
Georgia
1,600 constant 2022 US$
in 2022
Dominican Republic rank
28th
Georgia rank
30th
Average cost of multi drug-resistant tuberculosis treatment over time
- Dominican Republic
- Georgia
How they compare
Dominican Republic currently reports 1,650 constant 2022 US$ against 1,600 constant 2022 US$ in Georgia, a difference of 50 constant 2022 US$.
The two have swapped places 1 time across 5 shared years of data; in 2018 it was Georgia ahead.
Dominican Republic ranks 28th and Georgia ranks 30th of 92 countries.
Georgia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Dominican Republic | Georgia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 1,910 constant 2022 US$ | 2,808 constant 2022 US$ | 898 constant 2022 US$ | Georgia |
| 2020s | 1,966 constant 2022 US$ | 2,096 constant 2022 US$ | 130.33 constant 2022 US$ | Georgia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Dominican Republic or Georgia?
- Dominican Republic, at 1,650 constant 2022 US$ against 1,600 constant 2022 US$ in Georgia as of 2024.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Dominican Republic and Georgia?
- 50 constant 2022 US$, with Dominican Republic ahead.
- How many years of comparable data are there for Dominican Republic and Georgia?
- 5 years are reported by both, from 2018 to 2022.
- How do Dominican Republic and Georgia rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Dominican Republic ranks 28th and Georgia ranks 30th of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.